Early Chimerism Following Allogeneic Stem-Cell Transplant

Dartmouth Health

Status: Completed

Conditions: Allogeneic Stem-Cell Transplant

Treatments: Other: Chimerism Evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT03689907

D18125

NCI-2020-03008 (Other Identifier)

Details and patient eligibility

About

Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant cells to look at the DNA. Chimerism testing helps doctors predict graft rejection or recurrence of disease. Doctors at NCCC do chimerism testing routinely and it is usually done between 30 and 100 days after transplantation. The researchers believe that analyzing chimerism sooner than 30 days after transplant may help identify problems earlier, get patients treatment sooner, and increase the chances of a successful transplant.

The purpose of this study is to find out if doing chimerism testing earlier than the traditional approach is better for patient outcomes (about 14 days after transplantation rather than 30+ days). Information gained from this study can be used to help prevent some post-transplant complications such as graft loss, graft-versus-host disease, or even relapse for future patients.

Also, the researchers hope to learn more about chimerism testing of cells of patients with haploidentical donors (donors who are only a "half-match" - such as a parent or child of the recipient), because there have not been many chimerism analysis studies done in this population.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients will have been cleared by a Transplant Attending to undergo allogeneic stem cell transplant

Exclusion criteria

• Patients undergoing a second allogeneic stem cell transplant or beyond

Trial design

40 participants in 1 patient group

Allogeneic Stem-Cell Transplant Recipients

Description:

1. At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient. 2. At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients.

Treatment:

Other: Chimerism Evaluation